Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.68 -3.92 (-8.99%) Market Cap: 4.82 Bil Enterprise Value: 5.07 Bil PE Ratio: 0 PB Ratio: 18.04 GF Score: 38/100

Apellis Pharmaceuticals Inc at Citi BioPharma Conference Transcript

Sep 06, 2023 / 01:40PM GMT
Release Date Price: $42.75 (-0.81%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Welcome, everyone. I'm Yigal Nochomovitz. I'm one of the biotech analysts at Citi. I cover Apellis since the IPO many years ago. So it's my pleasure to have with me Cedric Francois, the Co-Founder, President and CEO; David Acheson, who is SVP of North America Commercial; and the CFO of Apellis, Tim Sullivan. So welcome, gentlemen. Thank you so much. It's great to have you here. It's amazing. It's been a year since we did this last fall.

Questions & Answers

Yigal Dov Nochomovitz;Cedric
Citigroup Inc., Research Division - Director

So let's start with some of the obvious debates. Maybe just as a first step, could you just give us an update on what you're seeing with the vasculitis events? How is that evolving? Is the rate the same? Is there anything new to say there relative to the last update you had a press release a few weeks ago, I think the end of August with some more data and the cadence of how often you'll continue to update the market on that important issue?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot